Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required.
COVID-19
Inactive vaccine
Neutralizing antibody
Sinovac
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
04
02
2022
accepted:
15
03
2022
pubmed:
29
3
2022
medline:
4
2
2023
entrez:
28
3
2022
Statut:
ppublish
Résumé
Despite high vaccination rates, increasing case numbers continue to be reported with the identification of new variants of concern, and the issue of durability of the vaccine-induced immune response remains hot topic. Real-life data regarding time-dependent immunogenicity of inactivated COVID-19 vaccines are scarce. We aimed to investigate the changes in the antibody at the different times after the second dose of the CoronaVac vaccine. The study included 175 HCWs vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses. Anti-spike/RBD IgG levels were measured first, third, and sixth months after the second dose. Chemiluminescent microparticle immunoassay (IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test, was used. Mean age of the participants was 38 ± 11.23 years (range between 22 and 66) of whom 119 (63.9%) were female, and 56 (32%) were male. Dramatic reductions were demonstrated in median antibody levels particularly in the infection-naïve group, comprising 138 HCWs compared to those with prior history of COVID-19 infection (n = 37) (p < 0.001). There was no difference between the two groups in terms of age, gender, blood groups, BMI, and comorbid diseases. While antibody positivity remained above 90% in the 6th month after two doses of inactivated vaccine in HCWs, the median titers of neutralizing antibodies decreased rapidly. The decrease was more rapid and significant in those with no history of prior COVID-19 infection. In this critical phase of the pandemic, where we are facing the dominance of the Omicron variant after Delta, booster doses have become vital.
Identifiants
pubmed: 35344137
doi: 10.1007/s11845-022-02984-1
pii: 10.1007/s11845-022-02984-1
pmc: PMC8958491
doi:
Substances chimiques
sinovac COVID-19 vaccine
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-25Informations de copyright
© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.
Références
WHO (2022) WHO director-general’s opening remarks at the media briefing on COVID-19-March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---20-march-2020 . Accessed 03 Feb 2022
Tanriover MD, Doğanay HL, Akova M et al (2021) CoronaVac study group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398(10296):213–222. https://doi.org/10.1016/S0140-6736(21)01429-X
Republic of Turkey Ministry of Health (2022) COVID-19 vaccination information platform. https://covid19asi.saglik.gov.tr/ . Accessed 03 Feb 2022
Gudbjartsson DF, Norddahl GL, Melsted P et al (2020) Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 383:1724–1734. https://doi.org/10.1056/NEJMoa2026116
doi: 10.1056/NEJMoa2026116
Wajnberg A, Mansour M, Leven E et al (2020) Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet 1:e283-289. https://doi.org/10.1016/S2666-5247(20)30120-8
doi: 10.1016/S2666-5247(20)30120-8
Centers for Disease Control and Prevention (CDC). SARS-CoV-2 variant classifications and definitions. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variantinfo.html . Accessed 03 Feb 2022
World Health Organization (2022) Variants of concern (VOC). https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ . Accessed 03 Feb 2022
Hitchings MDT, Ranzani OT, Scaramuzzini Torres MS et al (2021) Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: a testnegative case-control study. The Lancet Regional Health – Americas. 1:100025. https://doi.org/10.1101/2021.04.07.21255081
Garcia-Beltran WF, Lam EC, St Denis K et al (2021) Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184(9):2372-2383.e9. https://doi.org/10.1016/j.cell.2021.03.013
doi: 10.1016/j.cell.2021.03.013
World Health Organization (2020) Establishment of the WHO International standard and reference panel for anti-SARS-CoV-2 antibody. WHO/BS/2020.2403. https://www.who.int/publications/m/item/WHO-BS-2020.2403 . Accessed 03 Feb 2022
Abbott SARS-CoV-2 Immunoassays. https://www.corelaboratory.abbott/int/en/offerings/segments/infectious-disease/sars-cov-2 . Accessed 03 Feb 2022
Jara A, Undurraga EA, González C et al (2021) Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med 385(10):875–884. https://doi.org/10.1056/NEJMoa2107715
doi: 10.1056/NEJMoa2107715
Bochnia-Bueno L, De Almeida SM, Raboni SM et al (2021) Dynamic of humoral response to SARS-CoV-2 anti-nucleocapsid and spike proteins after CoronaVac vaccination. Diagn Microbiol Infect Dis 102(3):115597. https://doi.org/10.1016/j.diagmicrobio.2021.115597
doi: 10.1016/j.diagmicrobio.2021.115597
Kwok SLL, Cheng SMS, Leung JNS et al (2021) Waning antibody levels after vaccination with mRNA BNT162b2 and inactivated CoronaVac COVID-19 vaccines in Hong Kong blood donors. [Preprints] https://doi.org/10.1101/2021.12.05.21267330
Jantarabenjakul W, Chantasrisawad N, Puthanakit T et al (2021) Short-term immune response after inactivated SARS-CoV-2 (CoronaVac
Dinc HO, Saltoglu N, Can G et al (2022) Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection. Vaccine 40(1):52–58. https://doi.org/10.1016/j.vaccine.2021.11.051
doi: 10.1016/j.vaccine.2021.11.051
Muena NA, García-Salum T, Pardo-Roa C et al (2021) Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines. medRxiv 2021.05.17.21257197. [Preprint] https://doi.org/10.1101/2021.05.17.21257197
Tarke A, Sidney J, Methot N et al (2021) Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees. Cell Reports Med 2(7):100355. https://doi.org/10.1016/j.xcrm.2021.100355
doi: 10.1016/j.xcrm.2021.100355